My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC

Panelists discuss how genetic testing and RET-targeted therapies play a crucial role in guiding the treatment of advanced NSCLC, with a focus on optimizing first-line therapy and managing challenges in molecular testing and treatment sequencing.

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

December 10th 2024

Panelists discuss how the treatment approach for a 67-year-old man with stage IIIB+ non–small cell lung cancer (NSCLC) awaiting mutation testing involves balancing the urgency of initiating therapy with the importance of molecular testing to guide targeted treatment decisions.

EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

December 10th 2024

Panelists discuss how molecular testing is crucial in guiding treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the prevalence of mutations like BRAF, KRAS, MET, RET, and EGFR, and their impact on selecting targeted therapies.

EP. 3: Testing Methodologies and Standards in Metastatic NSCLC

December 17th 2024

Panelists discuss the various tests available for detecting genetic mutations in advanced non–small cell lung cancer (NSCLC), including next-generation sequencing (NGS), reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and Sanger sequencing, and explore whether one method is considered the “gold standard” according to the NCCN guidelines. They also address the appropriate use of circulating tumor DNA (ctDNA) testing, comparing it to tissue testing in this disease state.

EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing

December 17th 2024

Panelists discuss strategies for clinicians without access to in-house molecular testing, focusing on how to ensure appropriate turnaround times when outsourcing tests and share insights on the typical timeline for receiving biomarker testing results at their respective institutions.